Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin

Metabolism: Clinical and Experimental

Volumn 50, Issue 2, 2001, Pages 131-134

  Naruszewicz, Marek ^a   Klinke, Malgorzata ^a   Dziewanowski, Krzysztof ^a   Staniewicz, Anna ^a   Bukowska, Hanna ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; CYANOCOBALAMIN; FIBRINOGEN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRIDOXINE; TRIACYLGLYCEROL; UREA; URIC ACID; VITAMIN;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; DIALYSIS; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOGEN DEFECT; HUMAN; HYPERFIBRINOGENEMIA; HYPERHOMOCYSTEINEMIA; HYPERLIPOPROTEINEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; RISK FACTOR; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 0035109923     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2001.20174     Document Type: Article

References (24)

1. Morbidity and mortality CAPD and hemodialysis
2. Long-term cardiac morbidity and mortality during dialysis therapy
3. Hyperhomocysteinemia, hyperfibrinogenemia and lipoprotein(a) excess in maintenance dialysis patients: A matched case-control study
4. Vascular pathology of homocysteinemia: Implications for the pathogenesis
5. A prospective study of plasma homocyst(e)ine and risk of myocardial infraction in US physicians
6. Thiolation of low-density lipoprotein by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages
7. Fibrinogen and risk of cardiovascular disease: The Framingham Study
8. Lipoprotein(a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men
9. The oxidant stress of hyperhomocysteinemia
10. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism
11. Vitamins as homocysteine-lowering agents
12. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients
13. Determination of free and total homocysteine in human plasma by high performance liquid chromatography with fluorescence detection
14. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
15. Lipoprotein(a) in health disease
16. Homocysteine, folate, vitamin B6 and cardiovascular disease
17. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women
18. Water soluble vitamins in chronic hemodialysis patients and need for supplementation
19. Folate supplementation in the dialysis patient - Fragmentary evidence and tentative recommendations
20. Vitamin supplementation of patients receiving haemodialysis
21. N-Acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels
22. Oxidative stress and erythrocyte membrane fluidity in patients undergoing regular dialysis
23. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
24. Homocyst(e)ine, diet, and cardiovascular diseases: A statement for healthcare professionals from the Nutrition Committee, American Heart Association